• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Sunday 09/23/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Excelyte

  • 3:31 PM

    LITTLE RIVER, S.C., Jan. 26, 2016, IEVM, /PRNewswire/ — Integrated Environmental Technologies, Ltd. (OTCQB: IEVM) today announced that as of December 31, 2015, the Company had provided Excelyte® well maintenance treatments on 235 wells, an increase of 200 wells, or 571%, since December 31, 2014.  The Company performed 1,447 Excelyte® well maintenance treatments during the year ended December 31, 2015, generating $458,000 in revenue, an increase of $399,000, or 677%, from the amount of revenue generated during the year endedDecember 31,

    Read more
  • 3:55 PM

    SAN DIEGO, January 13, 2016, RGBP /PRNewswire/ — Regen BioPharma Inc. (OTCBB: RGBP) and (PINK: RGBP) provided the following update for its shareholders: Dear Shareholders, As we have now moved into 2016, I would like to take a moment to discuss Regen BioPharma’s overall progress during the last 12 months.  It is of note that Regen’s goal is to make a difference in the health of patients’ lives, particularly those suffering from cancer and disorders of the bone marrow.  By

    Read more
  • 3:16 PM

    NEW YORK, Dec. 15, 2015, LLTP, (GLOBE NEWSWIRE) — Lightlake Therapeutics Inc. (“Lightlake”) (OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive, and eating disorders, announced today that it has received a $2 million milestone payment from Adapt Pharma Limited (“Adapt”). This milestone payment was triggered by the U.S. Food and Drug Administration (“FDA”) approval of NARCAN® (naloxone hydrochloride) Nasal Spray for the emergency treatment of known or suspected opioid overdose, to be marketed by Adapt, Lightlake’s

    Read more
  • 3:15 PM

    VANCOUVER, Wash., Dec. 14, 2015, CYDY, (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced that it has been cleared by the FDA to conduct a Phase 2 trial for Graft versus Host Disease (GvHD), which is a life-threatening complication for patients undergoing stem cell transplants. CytoDyn currently is conducting a Phase 3 pivotal trial with its lead product candidate, PRO 140, for the

    Read more
  • Dario Logo
    3:47 PM

    A LabStyle distributor participated in the investment CAESAREA, Israel, November 19, 2015, OTCQB, DRIO /PRNewswire/ — LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario™ Diabetes Management Solution, today announced it has closed on an offering raising approximately $2.3 million in proceeds through the private placement of 7,648,267 shares of Common Stock and warrants to purchase 7,648,267 shares of Common Stock with existing shareholders and private investors including a member of the Company’s board of directors, employees and a Dario

    Read more
  • 8:28 PM

    Revolutionary device and procedure provides natural, safe, effective and economical fertility treatment option. MEDFORD, Mass., Nov. 3, 2015, OTC Pink, IVOB, /PRNewswire/ — INVO Bioscience, Inc. (OTC Pink: IVOB), a medical device company focused on treatment option for patients diagnosed with infertility, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company’s de novo request for the INVOcell™. As a result, INVOcell is the first intravaginal culture system granted marketing clearance in the United States, providing

    Read more
Public Wire Banner